| Followers | 200 |
| Posts | 25597 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Sunday, April 07, 2024 8:53:40 AM
Because you spend your time harassing people here. This is not a place for you. You might try your local park Karen. You apparently wanted to harass King’s College by posting here. This is not King’s College. You harassed regulators about this drug because King’s College was involved, Karen.
Quit it with the nonsense. You either are a person who makes up wild, nonsensical stories about your history and certifiable or you are a short just trying a new tactic. I think it’s likely the latter. I guess you could be both.
Some of the effort seems to have come about in the changeover from EMA regulation to UK only regulation, via BREXIT, so while the UK government made legal preparations for the rapid deployment of COVID-19 vaccines through amendments to regulations, the approval process still required a thorough review by the MHRA, with the CHM providing advice on safety, quality, and efficacy. It seems rather they needed to create a framework for stepping out fully from the slower EMA process. Because Europe operates by consensus, creating more efficient processes are not as easy for the European system in place now, but the UK had the opportunity and necessity to address these matters regardless of COVID because they had just left Europe.
https://post.parliament.uk/regulatory-approval-of-covid-19-vaccines-in-the-uk/
Quit it with the nonsense. You either are a person who makes up wild, nonsensical stories about your history and certifiable or you are a short just trying a new tactic. I think it’s likely the latter. I guess you could be both.
Some of the effort seems to have come about in the changeover from EMA regulation to UK only regulation, via BREXIT, so while the UK government made legal preparations for the rapid deployment of COVID-19 vaccines through amendments to regulations, the approval process still required a thorough review by the MHRA, with the CHM providing advice on safety, quality, and efficacy. It seems rather they needed to create a framework for stepping out fully from the slower EMA process. Because Europe operates by consensus, creating more efficient processes are not as easy for the European system in place now, but the UK had the opportunity and necessity to address these matters regardless of COVID because they had just left Europe.
https://post.parliament.uk/regulatory-approval-of-covid-19-vaccines-in-the-uk/
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
